Meeting
2024 ASCO Gastrointestinal Cancers Symposium
APC as a high-utility mutational biomarker that may identify subpopulations of patients with mutant RAS/BRAF and right-sided colorectal cancer (CRC) who derive benefit from EGFR inhibitors (EGFRi).
Authors
Ramya Thota
Intermountain Health, Murray, UT
Ramya Thota , Timothy Yeatman , Nishant Gandhi , Mingli Yang , Michael Schell , Lance Pflieger , Andrey Loboda , Michael Nebozhyn , Andrew Elliott , Joanne Xiu , George W. Sledge Jr., Moh'd M. Khushman , Emil Lou , Sanjay Goel , Warren Jack Pledger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 56)
DOI
10.1200/JCO.2024.42.3_suppl.56
Abstract #
56
Poster Bd #
D19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota
First Author: Sandra Algaze
Poster
2016 ASCO Annual Meeting
Genomic profiling and efficacy of anti-EGFR therapy in appendiceal adenocarcinoma.
First Author: Maria Ignez Freitas Melro Braghiroli
Poster
2016 Gastrointestinal Cancers Symposium
Genomic profiling and efficacy of anti-EGFR therapy in appendiceal adenocarcinoma.
First Author: Maria Ignez Freitas Melro Braghiroli